Bellerophon Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2013 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Bellerophon Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2013 to Q3 2023.
  • Bellerophon Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2023 was $21K, a 90.3% decline year-over-year.
  • Bellerophon Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2023 was $580K, a 19.9% decline year-over-year.
  • Bellerophon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $786K, a 30.2% decline from 2021.
  • Bellerophon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $1.13M, a 31% decline from 2020.
  • Bellerophon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2020 was $1.63M, a 24.1% decline from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 $580K $21K -$196K -90.3% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $776K $133K -$82K -38.1% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $858K $264K +$72K +37.5% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $786K $162K +$62K +62% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-31
Q3 2022 $724K $217K -$111K -33.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $835K $215K -$142K -39.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $977K $192K -$149K -43.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $1.13M $100K -$281K -73.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 $1.41M $328K -$78K -19.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $1.49M $357K -$21K -5.56% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $1.51M $341K -$127K -27.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
Q4 2020 $1.63M $381K -$10K -2.56% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-31
Q3 2020 $1.64M $406K +$232K +133% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $1.41M $378K -$201K -34.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $1.61M $468K -$540K -53.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q4 2019 $2.15M $391K -$448K -53.4% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-31
Q3 2019 $2.6M $174K -$330K -65.5% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $2.93M $579K -$317K -35.4% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $3.25M $1.01M +$292K +40.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $2.96M $839K +$132K +18.7% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-11
Q3 2018 $2.82M $504K -$252K -33.3% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 $3.08M $896K +$247K +38.1% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $2.83M $716K -$13K -1.78% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $2.84M $707K +$97K +15.9% Oct 1, 2017 Dec 31, 2017 10-K 2020-04-06
Q3 2017 $2.74M $756K -$23K -2.95% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $2.77M $649K -$119K -15.5% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-01
Q1 2017 $2.89M $729K +$128K +21.3% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q4 2016 $2.76M $610K +$103K +20.3% Oct 1, 2016 Dec 31, 2016 10-K 2019-03-14
Q3 2016 $2.66M $779K +$342K +78.3% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 $2.31M $768K +$405K +112% Apr 1, 2016 Jun 30, 2016 10-Q 2016-08-09
Q1 2016 $1.91M $601K +$157K +35.4% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-15
Q4 2015 $1.75M $507K Oct 1, 2015 Dec 31, 2015 10-K 2018-03-15
Q3 2015 $437K +$174K +66.2% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-08
Q2 2015 $363K -$401K -52.5% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
Q1 2015 $444K Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q3 2014 $263K Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-12
Q2 2014 $764K Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-14
Q1 2013 $271K Jan 1, 2013 Mar 31, 2013 10-Q 2015-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.